Vanguard Group’s Derma Sciences, Inc. Common Stock (DE) DSCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-843,287
| Closed | -$4.38M | – | 4126 |
|
|
2016
Q4 | $4.38M | Buy |
843,287
+11,133
| +1% | +$52.3K | ﹤0.01% | 3110 |
|
|
2016
Q3 | $3.89M | Buy |
832,154
+29,276
| +4% | +$137K | ﹤0.01% | 3127 |
|
|
2016
Q2 | $3.16M | Buy |
802,878
+8,376
| +1% | +$31.3K | ﹤0.01% | 3194 |
|
|
2016
Q1 | $2.46M | Buy |
794,502
+113,747
| +17% | +$381K | ﹤0.01% | 3299 |
|
|
2015
Q4 | $3.11M | Buy |
680,755
+90,325
| +15% | +$428K | ﹤0.01% | 3216 |
|
|
2015
Q3 | $2.78M | Buy |
590,430
+28,033
| +5% | +$181K | ﹤0.01% | 3223 |
|
|
2015
Q2 | $4.03M | Sell |
562,397
-20,579
| -4% | -$155K | ﹤0.01% | 3117 |
|
|
2015
Q1 | $4.94M | Buy |
582,976
+39,335
| +7% | +$335K | ﹤0.01% | 3006 |
|
|
2014
Q4 | $5.06M | Buy |
543,641
+14,644
| +3% | +$127K | ﹤0.01% | 2898 |
|
|
2014
Q3 | $4.41M | Buy |
528,997
+29,136
| +6% | +$270K | ﹤0.01% | 2903 |
|
|
2014
Q2 | $5.78M | Buy |
499,861
+6,436
| +1% | +$66K | ﹤0.01% | 2765 |
|
|
2014
Q1 | $6.26M | Buy |
493,425
+209,449
| +74% | +$2.71M | ﹤0.01% | 2714 |
|
|
2013
Q4 | $3.07M | Buy |
283,976
+20,805
| +8% | +$242K | ﹤0.01% | 3021 |
|
|
2013
Q3 | $3.26M | Buy |
263,171
+17,567
| +7% | +$243K | ﹤0.01% | 2941 |
|
|
2013
Q2 | $3.28M | Buy |
+245,604
| New | +$3.16M | ﹤0.01% | 2882 |
|
Other funds holding DSCI
Vanguard Group's DSCI Position: Q1 2017 in Review
Vanguard Group sold out of Derma Sciences, Inc. Common Stock (DE) (DSCI) in Q1 2017, closing a stake of 843,287 shares — an estimated $4.38M sold.
Vanguard Group first reported a position in DSCI in Q2 2013 and held it in 15 quarters. The position peaked at $6.26M in Q1 2014. 1 fund tracked by Wall St. Rank holds DSCI as of Q1 2017.
- Vanguard Group reported no remaining Derma Sciences, Inc. Common Stock (DE) position as of Q1 2017 after selling out during the quarter.
- Vanguard Group sold 843,287 Derma Sciences, Inc. Common Stock (DE) shares in Q1 2017, an estimated $4.38M.
- Vanguard Group first reported a position in Derma Sciences, Inc. Common Stock (DE) in Q2 2013 and held it in 15 quarters.
- Vanguard Group's Derma Sciences, Inc. Common Stock (DE) position peaked at $6.26M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Derma Sciences, Inc. Common Stock (DE) as of Q1 2017.
Based on Vanguard Group's 13F filing for Q1 2017, filed 12 May 2017.